BUSINESS

Kaken’s Hyperhidrosis Drug Ecclock Now Available in South Korea

January 20, 2026

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

Kaken Pharmaceutical said on January 19 that its primary axillary hyperhidrosis treatment Ecclock (sofpironium bromide) has been launched in South Korea by local partner Dong-Wha Pharm.Dong-Wha markets the drug under an exclusive development and commercialization agreement signed with Kaken in…

To read the full story

Kaken’s Hyperhidrosis Drug Ecclock Gets Approval in South Korea
September 3, 2025
Hyperhidrosis Drug Ecclock Filed in South Korea: Kaken
October 6, 2023
Kaken, Dong-Wha Ink License Pact for Ecclock in South Korea
June 6, 2023

BUSINESS

Nippon Shinyaku to Take Over UCB’s Fintepla in Japan from April
February 25, 2026
Opdivo-Yervoy Expands Label for Colorectal Cancer in South Korea
February 25, 2026
Daiichi Sankyo Taps Ex-Novartis CMO John Tsai as R&D Head
February 24, 2026
Shionogi to Absorb Torii in April 2027
February 24, 2026
Sumitomo, Partners Launch Malaria Vaccine Project Targeting Mid-2030s Approval
February 24, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COLUMN

The Strategic MSL: Beyond Data Delivery, It’s About Impact

By Philip Carrigan

I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…

COMMENTARY

Hisamitsu’s MBO: Is Shareholder Accountability Trust-Building or a Shackle?

By Hayate Horiguchi

Following Hisamitsu Pharmaceutical’s decision to go private through a roughly 400 billion yen management buyout (MBO), industry observers are weighing…